BrainChip Holdings Limited provided its quarterly activities report for the period ending 31 March 2026, with notable progress on production timelines and strategic partnerships that highlight the company’s advancing commercialisation of neuromorphic edge AI technology. The most significant development is the reaffirmation that BrainChip’s first high-volume production silicon device, the AKD1500 neuromorphic processor, remains on track for production availability in the third quarter of 2026, with deliveries commencing in July.
The AKD1500 represents a critical inflection point for BrainChip’s commercial trajectory. The company anticipates receiving approximately 70,000 units in its first production run, with deliveries spanning four to six weeks from July 2026. This represents the transition from development and evaluation phases into revenue-generating production, a milestone that investors have tracked closely. The processor is positioned as a dedicated neuromorphic AI co-processor optimised for ultra-low power, always-on inference in edge systems, targeting defence, industrial sensing, robotics and embedded IoT markets. Customer evaluation programs continue in parallel with final production preparations, suggesting the company is building a pipeline ahead of volume availability.
Beyond the AKD1500, BrainChip has initiated development of the AKD2500, its next-generation neuromorphic processor implemented on Taiwan Semiconductor Manufacturing Company’s 12-nanometre process technology. This represents a material advancement in the company’s Akida 2.0 roadmap. The staged development program carries an anticipated cost of approximately US$2.5 million, with prototype silicon tape-out expected in the second half of calendar 2026. The use of TSMC’s widely adopted manufacturing node could broaden customer adoption by enabling evaluation of next-generation neuromorphic performance on a familiar platform.
Customer traction remains a key metric for investors assessing commercialisation progress. Customer cash inflows during the quarter reached US$0.7 million, representing improvement from US$0.4 million in the prior quarter. While absolute volumes remain modest, the trajectory is encouraging. The company executed multiple strategic licensing and collaboration agreements during the period, including a global Akida 2.0 licensing agreement with EDGEAI, establishing a new royalty-bearing customer relationship. More significantly, BrainChip was selected by ForwardEdge ASIC, a Lockheed Martin subsidiary, as the neuromorphic AI provider for future custom ASIC platforms, suggesting validation from a major defence contractor.
Product announcements included the launch of the AkidaTag reference platform and immediate availability of Akida Pico via cloud-based FPGA access, tools designed to accelerate early customer engagement and proof-of-concept development. These platform expansions lower barriers to evaluation and design-win conversion. Investors should monitor the July 2026 commencement of AKD1500 deliveries and quarterly updates on customer adoption rates and revenue realisation. Additional milestones include the AKD2500 prototype tape-out expected in the second half of 2026. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About BrainChip Holdings Limited (ASX: BRN)
BrainChip is an Australian technology company that develops neuromorphic artificial intelligence hardware and software solutions for edge computing applications. The company’s core products include the Akida neuromorphic processor, which mimics the human brain’s neural architecture to deliver ultra-low power AI processing, and MetaTF software for developing and training neural networks. BrainChip serves markets in North America, Europe, Asia, and the Middle East, targeting applications in security, surveillance, autonomous vehicles, and industrial automation.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
